Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_assertion type Assertion NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_head.
- NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_assertion description "[Because these tumours tend to be less sensitive than other types of GTD to chemotherapy, the most successful regimen to date has been with EMA/CO or EMA/EP.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_provenance.
- NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_assertion evidence source_evidence_literature NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_provenance.
- NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_assertion SIO_000772 14614893 NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_provenance.
- NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_assertion wasDerivedFrom befree-2016 NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_provenance.
- NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_assertion wasGeneratedBy ECO_0000203 NP420563.RAVVhAG09iNEcdMR_Hqq2DNM54Q9n1wGteGjpliqD7M-8130_provenance.